Page 35 - 79_02

C.
Avendaño

organo-­-tellurium
compound
AS101
against
Enterobacter
cloacae”;
J.
Antimicrob.

Chemother.,
67,
2165-­-2172.

12. Indenbaum,
V.;
Bin,
H.;
Makarovsky,
D.;
Weil,
M.;
Shulman,
L.
M.;
Albeck,
M.;
Sredni,
B.;

Mendelson,
E.;
(2012)
“In
vitro
and
in
vivo
activity
of
AS101
against
West
Nile
virus

(WNV)”;
Virus
Res.,
166,
68-­-76.

13. Sredni-­-Kenigsbuch,
D.;
Sota,
M.;
Shohat,
B.;
Ben-­-Amitai,
D.;
Chan,
C.
C.;
David,
M.;
(2008)

“The
novel
tellurium
immunomodulator
AS101
inhibits
interleukin-­-10
production
and

p38
MAPK
expression
in
atopic
dermatitis”;
J.
Dermatol.
Sci.;
50,
232-­-235.

14. Sredni,
B.;
Gal,
R.;
Cohen,
I.
J.;
Dazard,
J.
E.;
Givol,
D.;
Gafter,
U.;
Motro,
B.;
Eliyahu,
S.;

Albeck,
M.;
Lander,
H.
M.;
Kalechman,
Y.;
(2004)
“Hair
growth

induction
by
the
Tellurium

immunomodulator
AS101:
association
with
delayed
terminal
differentiation
of
follicular

keratinocytes
and
ras-­-dependen
up-­-regulation
of
KGF
expression”;
FASEB
J.,
18,
400-­-402.

15. (a)
Sredni,
B.;
Albeck,
M.;
Tichler,
T.;
Shani,
A.;
Shapira,
J.;
Bruderman,
I.;
Catane,
R.;

Kaufman,
B.;
Kalechman,
Y.;
(1995)
“Bone
marrow-­-sparing
and
prevention
of
alopecia
by

AS101
in
non-­-small-­-cell
lung
cancer
patients
treated with
carboplatin
and
etoposide”,
J.

Clin.
Oncol.,
13,
2342-­-2353.
(b)
Sredni,
B.;
Xu,
R.
H.;
Albeck,
M.;
Gafter,
U.;
Gal,
R.;
Shani,
A.;

Tichler,
T.;
Shapira,
J.;
Bruderman,
I.;
Catane,
R.;
Kaufman,
B.;
Whisnant,
J.
K.;
Mettinger,
K.

L.;
Kalechman,
Y.;
(1996)
“The
protective
role
of
the
immunomodulator
AS101
against

chemotherapy-­-induced
alopecia:
studies
on
human
and
animal
models”,
Int.
J.
Cancer.
65,

97-­-103.

16. (a)
Makarovsky,
D.;
Kalechman,
Y.;
Sonino,
T.;
Freidkin,
I.;
Teitz,
S.;
Albeck,
M.;
Weil,
M.;

Geffen-­-Aricha,
R.;
Yadid,
G.;
Sredni,
B.;
(2003)
“Tellurium
compound
AS101
induces
PC12

differentiation
and
rescues
the
neurons
from
apoptotic
death”,
Ann.
N.
Y.
Acad.
Sci.,
1010,

659-­-666.
(b)
Sredni,
B.;
Geffen-­-Aricha;
R.;
Duan,
W.
Z.;
Albeck,
M.;
Shalit,
F.;
Lander,
H.
M.;

Kinor,
N.;
Sagi,
O.;
Albeck,
A.;
Yosef,
S.;
Brodsky,
M.;
Sredni-­-Kenigsbuch,
D.;
Sonino,
T.;

Longo,
D.
L.;
Mattson,
M.
P.;
Yadid,
G.;
(2007)
“Multifunctional
tellurium
molecule
protects

and
restores
dopaminergic
neurons
in
Parkinson's
disease
models”;
FASEB
J.,

21,

1870-­-
1883.

17. Halperin-­-Sheinfeld,
M.,
Gertler,
A.;
Okun,
E.;
Sredni,
B.;
Cohen,
H.
Y.;
(2012)
“The
Tellurium

compound,
AS101,
increases
SIRT1
level
and
activity
and
prevents
type
2
diabetes”;

Aging,
4,
436-­-447. AGING, June 2012, Vol. 4, No 6

18. Kalechman,
Y.;
Shani,
A.;
Sotnik-­-Barkai,
I.;
Albeck,
M.;
Sredni,
B.;
(1993)
“The
protective

role
of
ammonium
trichloro(dioxoethylene-­-O,O')tellurate
in
combination
with
several

cytotoxic
drugs
acting
by
different
mechanisms
of
action”,
Cancer
Res.,
53,
5962-­-5969.

19. Hayun,
M;
Naor,
Y.;
Weil,
M.;
Albeck,
M.;
Peled,
A.;
Don,
J.;
Haran-­-Ghera,
N.;
Sredni,
B.;

(2006)
“The
immunomodulator
AS101
induces
growth
arrest
and
apoptosis
in
multiple

myeloma:
association
with
the
Akt/survivin
pathway”;

Biochem.
Pharmacol.,
72,
1423-­-
1431.

206